Clinical trial

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Sitagliptin Normalized identity: sitagliptinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2009-07-06

PhasePHASE4

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

End Stage Renal Diseaseverified · MONDO: end stage renal failure

Interventions

PlaceboDRUG

SitagliptinDRUG · verified · RxNorm: sitagliptin

Sponsors & collaborators

University of Nebraskalead sponsor

Mapped research locations

OmahaNebraska, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00936663 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.